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PAOLO MARINO, MD, LUISA ZANOLLA, MD, PIER0 ZARDINI, MD ON BEHALF OF THE GRUPPO 
ITALIANO PER LO STUDIO DELLA STREPTOCHINASI NELL'INFARTO MIOCARDICO (GISSI) 
It has been shown that streptokinase administration at the 
time of acute myocardial infarction reduces mortality sig- 
nificantly, and that this reduction in mortality should he 
related to salvage of jeopardized myocardium and preser- 
vation of left ventricular function. To better define the 
relation between thrombolytic therapy and left ventricular 
modeling and function after acute myocardiai infarction, 
331 consecutive patients enrolled in the Gruppo Itaiiano per 
lo Studio della Streptochinasi neli’btfarto Miocardico trial 
were studied by two-dimensional echocardiography just 
before discharge from the hospital. A 6 month follow-up 
examination was also available in 232 of these patients. 
Ventricular volumes were computed from an apical four 
chamber view, according to a previously published algo- 
rithm. An infarct size index was also semiquantitatively 
assessed, according to the number of akinetic and dyski- 
netic segments in an 11 segment left ventricular model. 
At predischarge examination, the 161 patients assigned 
to streptokinase treatment showed smaller ventricular vol- 
umes (end-diastolic volume 119.3 f 49.7 versus 134.5 + 
57.8 ml [p = O.Oll]; end-systolic volume 65.4 f 36.4 versus 
74.9 + 45.7 ml [p = 0.0361) and smaller regional wall 
motion index (2.2 f 1.9 versus 2.7 -C 1.9 segments; p = 
0.019) compared with values in the 170 patients assigned to 
The GISSI (Gruppo Italiano per lo Studio della Streptochi- 
nasi nell’Infarto Miocardico) trial has shown that throm- 
bolytic treatment with intravenous streptokinase reduces 
in-hospital mortality by 18% (1) and that this beneficial 
effect extends beyond the hospital phase to at least 1 year 
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standard care; there was no difference in ejection fraction 
(46.6 f 14.1 versus 45.9 + 14.9%; p = 0.64). For both 
groups of patients, there was a significant relation between 
end-systolic volume and regional wall motion index (p < 
0.001); for large and similar extents of infarct size, ventric- 
ular volume was smaller in patients assigned to throm- 
bolytic treatment than in patients assigned to standard 
care. 
At 6 months’ follow-up, the differences in volume and 
regional dysfunction detected at the early examination 
persisted: 110.8 + 47.6 versus 127.9 + 53.8 ml for end- 
diastolic volume (p = O.OOl), 56.3 + 33.6 versus 69.4 2 
42.1 ml for end-systolic volume (p = 0.001) and 1.8 + 1.8 
versus 2.3 & 1.8 segments for regional wail motion index 
(p = 0.001). Again, for comparable extents of infarct size, 
end-systolic volume was smaller in patients who received 
streptokinase (n = 110) than in those assigned to conven- 
tional treatment (n = 122). 
It is concluded that streptokinase improves left ventric- 
ular modeling and function in patients with myocardial 
infarction, reducing the extent of regional wail motion 
abnormalities and lessening postinfarction ventricular diia- 
tion. The beneficial effects persist up to 6 months. 
(J Am Co11 Cardiol1989;14:1149-58) 
(2). As the reduction of in-hospital and late mortality after 
thrombolytic treatment is postulated to be related to the 
beneficial effects of reperfusion of the infarct-related artery, 
with salvage of jeopardized myocardium and preservation of 
myocardial function (3) a two-dimensional echocardio- 
graphic project (4) was prospectively devised on a subgroup 
of the GISSI population to assess the potential effects of 
intravenous streptokinase on left ventricular modeling and 
function after myocardial infarction. 
Thus, a cohort of patients enrolled in the trial underwent 
two-dimensional echocardiography 1) just before discharge 
from the hospital (approximately 2 weeks after the onset of 
acute myocardial infarction), and 2) at 6 month follow-up. 
01989 by the American College of Cardiology 0735.1097/89/$3.50 
1150 MARINO ET AL. 
STREPTOKINASE AND VENTRICULAR FUNCTION 
JACC Vol. 14, No. 5 
November I, 1989: 1149-58 
The purpose was to assess whether left ventricular volumes, 
ejection fraction and a qualitatively estimated regional wall 
motion index differed between the treated and untreated 
population at the subacute phase of the illness, and, if this 
was the case, whether the difference persisted also in the 
chronic phase of the disease. 
Methods 
Study design. The design and method of the GISSI trial 
have been described in detail previously (I). Briefly, GISSI 
was a controlled unblinded trial with central randomization. 
Patients were considered eligible for the trial if 1) they had 
chest pain accompanied by ST segment elevation or depres- 
sion 2 1 mm in any limb lead of the electrocardiogram (ECG) 
or of 2 mm in any precordial lead, or both, and 2) they were 
admitted to the coronary care unit within 12 h from the onset 
of symptoms. The usual exclusion criteria for thrombolytic 
therapy were applied (1). Patients assigned to streptokinase 
treatment received 1.5 million U intravenously over 1 h. 
Over an approximately 12 month period, all consecutive 
patients recruited for the GISSI trial at the 12 hospitals that 
previously agreed to take part in the echocardiographic 
project underwent two-dimensional echocardiography ac- 
cording to the protocol that follows. 
Echocardiographic protocol. In-hospital two-dimensional 
echocardiographic examination was performed approxi- 
mately 2 weeks after admission (mean 13.7 5 2.8 days, range 
6 to 28), with use of parasternal, apical and subcostal views 
(4,5), and images were stored on videotape. End-diastolic 
and end-systolic volumes were computed according to a 
previously published algorithm (6) that related the left ven- 
tricular volume to a half-ellipsoid and a half-cylinder geom- 
etry. An apical four chamber ventricular long-axis and a 
perpendicular mid-ventricular septum to lateral wall distance 
was used, assuming a circular left ventricular cross-sectional 
configuration (Fig. 1). End-diastole was defined as the frame 
coincident with the onset of the QRS complex on the ECG, 
and end-systole as the subsequent frame with the smallest 
ventricular cavity area. Ejection fraction was also computed 
according to the usual formula: ([end-diastolic volume - 
end-systolic volumellend-diastolic volume) x 100. A re- 
gional wall motion index was semiquantitatively assessed 
according to the number of akinetic and dyskinetic segments 
in an 11 segment left ventricular model derived from the one 
proposed by Edwards et al. (7), and modified to consider the 
apex as a single segment (Fig. 2). Studies were considered 
adequate for analysis only when each of these 11 segments 
was included in at least one view. 
The recorded examinations were reviewed and analyzed 
by the staff of the echocardiographic laboratory where the 
examination had been performed. In particular, two observ- 
ers, unaware of each other and without advance knowledge 
of the patients’ clinical data, performed quantitative and 
1 LA 
I J 
Figure 1. Schematic drawing of the echocardiographic four chamber 
view used for volume computation. The algorithm adopted relates 
the ventricular volume to a half-ellipsoid and a half-cyiinder geom- 
etry, with use of the ventricular long axis (L) and the perpendicular 
mid-ventricular septum to lateral wall distance (D). The ventricular 
cross-sectional configuration is assumed to be circular. LA = left 
atrium; LV = left ventricle. 
semiquantitative analysis of the recorded images. The re- 
sults of these two observations of the semiquantitative data 
had to be compared and, where discrepancies arose, these 
studies had to be reviewed and agreement obtained. 
Homogeneity control and interlaboratory reproducibility. 
A homogeneity control on the quantitative data was per- 
formed by the coordinating center at the end of the recruit- 
ment period, comparing the measurements performed in 
each center with the set of those performed in all the 
remaining laboratories. The presence of a statistically signif- 
icant difference was considered as an exclusion criterion for 
data submitted by that specific laboratory. 
Interlaboratory reproducibility was also centrally as- 
sessed by review of approximately 10% of the examinations, 
Figure 2. The 11 segment left ventricular model adopted to assess 
the extent of regional wall motion abnormalities in the three echo- 
cardiographic approaches. The model is derived from that proposed 
by Edwards et al. (7), and modified considering the apex as a single 
segment (see text for details). 
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Table 1. Baseline Characteristic of 331 Patients 
SK C 
(n == 161) (n = 170) p Value 
Female (‘Z’r) 16.8 10.0 <o. IO 
Age (yr) 57.4 t- 12.9 55.8 + 13.1 0.28 
565 (7) 75.2 X0.6 
>6S (Q) :4.8 19.4 
<0.X) 
Time from the onset of 230 t 144 237 % 157 0.68 
symptoms (min) 
53 h (%) ‘0.9 53.: 
>3to6hIc/rl 35.4 28.2 co.30 
;6 h VZ7r) 13.7 18.1 
Previous infarct (%) 
No 86.3 x2.9 
Yes 13.7 16.5 io.50 
Doubtful 0.0 0.6 
Site of infarct (%) 
Anterior 29.8 35.9 
Inferior 13.5 31.1 
Lateral 3.1 4.1 10.70 
Multiple location 22.4 21.X 
ST depression 10.6 7.0 
Undefined 0.6 0.0 
C = control group: SK = streptokinase-treated group. 
randomly selected from those performed by each laboratory. 
Twenty-nine examinations were thus centrally reviewed 
without knowledge of patient data by one experienced 
observer. who repeated quantitative and semiquantitative 
measurements. The interlaboratory reproducibility of quan- 
titative measurements was then assessed calculating the 
difference between the two readings, expressed as a percent- 
age of their arithmetic mean. The reproducibility of semi- 
quantitative data was assessed according to the percentage 
of segments with interlaboratory agreement. 
Follow-up. The echocardiographic examination was re- 
peated 6 months later in patients who had no major clinical 
events after hospital discharge. 
Patient selection. Of 680 patients recruited for the GISSI 
trial at the 12 participating hospitals, 301 (44.3%) were not 
included in the echocardiographic project because of I) 
inadequate quality of the echocardiographic images (101: 
14.9’%), 2) unconfirmed diagnosis of acute myocardial infarc- 
tion (30; 4.4%). 3) new coronary events (17: 2.5%), 4) death 
(58; 8%). or 5) organizing problems (95. 14%). Forty-eight 
of the remaining 379 patients were excluded at the homoge- 
neity control because their examinations had been per- 
formed in a laboratory whose volume measurements showed 
a significant underestimation relative to the mean of all the 
other laboratories participating to the project. 
Study patients (Table 1). Echocardiographic data were 
therefore available in 331 patients (47.8%). There were 287 
men and 44 women: their mean age was 57.8 t- 10.1 years. 
The time from onset of symptoms to randomization averaged 
237 ? 151 min. Fifty patients had previous myocardial 
p= 011 p-.036 p= 636 p= 01.9 
EDV ESV EF RWMi 
Figure 3. Bar graph showing end-diastolic (EDV) and end-systolic 
volume (ESVI, ejection fraction (EF) and regional wall motion index 
(RWMi) obtained from the predischarge echocardiogram in patients 
who received streptokinase (SK) or conventional treatment (Cl. 
Although ejection fraction does not differ between the two groups. 
ventricular volumes and regional wall motion index are significantly 
smaller in streptokinase-treated patients. seg = segment. 
infarction. One hundred sixty-one patients were allocated to 
the streptokinase group and 170 to the control group. Base- 
line characteristics were similar for patients assigned to 
thrombolytic or conventional treatment. The infarct site had 
been defined by the GIN committee, according to previ- 
ously described criteria (I). 
Statistical methods. All the results are expressed as mean 
values 5 I SD. Differences in means between the treatment 
groups were assessed by t statistics. Evaluation of changes 
over time was made with paired t tests. Two-sided p values 
are reported. Contingency table analysis was performed for 
categorical variables. The relation of end-systolic volume to 
regional wall motion index for streptokinase-treated and 
control patients was evaluated by linear regression analysis 
according to the least square method. 
Results 
Reproducibility analysis. The average percent interlab- 
oratory reproducibility was 6.9 t 7.9% for end-diastolic 
volume, 8.8 ? 10.7% for end-systolic volume and 6.4 ? 5.3% 
for ejection fraction. Semiquantitative regional wall motion 
assessment showed a 90% interlaboratory agreement. 
Echocardiographic results (Fig. 3 and 4). Patients as- 
signed to streptokinase treatment, compared with the con- 
trol group, showed significantly, smaller values of end- 
diastolic volume (119.3 * 49.7 versus 134.5 5 57.8 ml; p = 
0.011) and end-systolic volume (65.4 i 36.4 versus 74.9 ? 
45.7 ml; p = 0.036) (Fig. 3); there was no difference in 
ejection fraction (46.6 ? 14.1 versus 45.9 i- 14.9%; p = 
0.64): the regional wall motion index was significantly 
smaller in the streptokinase-treated patients (2.2 + 1.9 
versus 2.7 2 I .9 segments; p = 0.019). For both groups there 
was a significant relation between end-systolic volume and 
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Figure 4. Plots of end-systolic volume versus regional wall motion 
index as assessed from the predischarge (A) and the 6 month 
echocardiogram (B). There is a strong relation between the two 
variables at both examinations: for large and similar extent of 
asynergy, end-systolic volume is smaller in patients who received 
streptokinase (SK) than in patients assigned to conventional treat- 
ment (C). Although the difference between the slopes of the two 
regression lines does not reach statistical significance, it suggests a 
restraining effect of streptokinase on the process of infarct expan- 
sion. seg = number of segments. 
regional wall motion index (Fig. 4A); the regression equation 
for streptokinase-treated patients was y = 12.2x t 38 ml, r = 
0.62, p < 0.001; for patients assigned to conventional treat- 
ment it was y = 15x + 33.9 ml, r = 0.64, p < 0.001. 
Interestingly, for large and similar extent of asynergy, end- 
systolic volume was slightly smaller in the streptokinase 
than that in the control group (Fig. 4A), but the difference 
between the slopes of the regression lines was not significant 
(p < 0.1). 
Although no subgroup analysis was explicitly planned by 
the protocol, stratification of the population was also per- 
formed according to 1) time elapsed from the onset of 
symptoms to randomization, 2) age, 3) previous myocardial 
infarction, and 4) site of myocardial infarction in accordance 
with the main trial (1). However, when even a very large 
trial, with a clearly positive overall result, is subjected to 
many subgroup analyses, false negative results in some 
subgroups must be expected (8). Thus, reliable identification 
of subgroups of patients among whom treatment is or is not 
advantageous may be impossible. Data from the subgroup 
analysis has to be considered in this perspective. 
Subgroups by hours from onset of symptoms (Table 2). 
When patients were stratified by hours elapsed before ran- 
domization (~3, 3 to 6, >6 h), only those assigned to 
thrombolysis between 3 and 6 h from the onset of pain 
exhibited significantly smaller volumes and less regional dys- 
function compared with those assigned to conventional treat- 
ment (p = 0.027,0.012 and 0.006, respectively) with a trend to 
higher values of ejection fraction (p = 0.08). In those patients 
who received streptokinase after 6 h or within 3 h, ventricular 
volumes and regional wall motion index were smaller com- 
pared with those in patients who did not receive the drug, but 
the differences did not reach statistical significance. 
Subgroups by age (Table 3). The analysis of the sub- 
groups obtained stratifying the patients according to age 
(565, >65 years) revealed, in younger patients, smaller 
end-systolic and end-diastolic ventricular volumes and re- 
gional wall motion index in the streptokinase group, but the 
difference was not significant. When patients >65 years were 
considered, the difference between streptokinase-treated 
and control patients was greater, reaching statistical signifi- 
cance for volumes (p = 0.007 and p = 0.12, respectively) and 
regional wall motion (p = 0.006). 
Subgroups by previous myocardial infarction (Table 4). 
When patients were grouped according to the history of 
previous myocardial infarction, only patients without previ- 
ous infarction showed significantly smaller values of end- 
diastolic and end-systolic volume (p = 0.019 and p = 0.079, 
respectively) and smaller regional dysfunction (p = 0.007). 
Subgroups by site of myocardial infarction (Table 5). 
Finally, the analysis of subgroups stratified according to 
infarct site showed, in the streptokinase-treated patients 
with anterior infarction only, significantly smaller ventricu- 
lar volumes (p = 0.019 and p = 0.069 for end-diastolic and 
Table 2. Echocardiographic Data by Hours From Onset of Symptoms in 331 Patients 
53 h 3to6h >6 h 
SK C p Value SK C p Value SK C p Value 
No. of patients 82 91 57 48 22 31 
EDV (ml) 123.9 + 51.3 129.5 + 49.6 0.476 114.6? 41.1 135.7 s 56.6 0.027 114.3 2 63.2 147.3 2 78.3 0.108 
ESV (ml) 68.7 + 36.5 69.6 + 40.4 0.877 59.6 ? 31.1 77.8 ? 42.7 0.012 67.6 f 47.4 86.2 ? 61.5 0.241 
EF (%) 46.1 + 36.5 47.4 t 14.9 0.536 49.5 ? 15.7 44.1 + 15.9 0.079 41.3 ? 13.2 44.2 ? 13.2 0.433 
RWMi 2.3 + 1.9 2.7 2 1.9 0.276 2.2 + 1.7 2.9 + 2.2 0.006 2.1 + 2.0 2.8 + 1.9 0.220 
(no. of segments) 
C = control group; EDV = end-diastolic volume; EF = ejection fraction; ESV = end-systolic volume: RWMi = regional wall motion index; SK = 
streptokinase group. 
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Table 3. Echocardiographic Data by Age in 331 Patients 
565 yr 
SK C p Value SK 
>65 yr 
C p Value 
No. of patients 121 137 
EDV (ml) 121.9 2 52.5 132.6 t 58.4 
ESV (ml) 67.0 5 38.1 73.2 2 46.6 
EF (“r) 46.S ? 14.1 46.6 ? If;.? 
RWMi 2.3 t 1.9 2.6 2 I.9 
(no. of segments) 
Abbreviations as in Table 2. 
end-systolic volume, respectively) than those in the control 
group. Although the streptokinase-treated patients with a 
nonanterior infarct location similarly tended to have signifi- 
cantly smaller volumes than those in the control group, the 
trend never reached statistical significance. 
In each subgroup, patients were well balanced between 
streptokinase and conventional treatment in relation to 
hours elapsed before randomization, age, history and site of 
myocardial infarction. The anterior infarct location, only, 
was preponderant in the control group for patients treated 
after 6 h (18.2% versus 45.2%; p = 0.038) or aged >65 years 
(35.0% versus 57.6%: p = 0.045), whereas the percentage of 
patients treated between 3 and 6 h and aged >65 years was 
significantly higher in the streptokinase group (38.6 versus 
20.8%; p = 0.03). 
Six month follow-up (Tables 6 and 7). The 6 month 
follow-up examination was performed in 232 patients 
(70.1%). The remaining 99 (29.9%) were lost to follow-up 
because 1) no information was sent from the enrolling center 
(50; 15.1%); 2) the patient was lost to the enrolling center 
(26; 7.9%); 3) a new coronary event had occurred (4; 1.2%): 
4) the patient died (15; 4.5%); and 5) examination was 
technically inadequate (4; 1.2%). 
When we compared patients with and without follow-up 
examination, we found no difference in the percent of 
subjects assigned to streptokinase treatment, percent of 
women, age, time from the onset of symptoms to random- 
ization and incidence of previous myocardial infarction; only 
end-diastolic volume. end-systolic volume and regional wall 
40 33 
0.126 Ill.3 ? 39.8 142.2 -+ 55.0 0.007 
0.246 60.3 + 30.5 81.9 2 41.4 0.012 
0.93 I 37.2 2 14.4 42.9 + 13.8 0.194 
0.193 2.2 i 1.7 3.4 t I.9 0.006 
motion index were larger (p < 0.0001 for all) and ejection 
fraction lower (p < 0.0001) in patients lost to follow-up. 
These differences likely reflect the differences between the 
two groups in site of myocardial infarction (p < 0.01). 
Baseline characteristics of the 232 patients with follow-up 
examination were similar in the thrombolytic and conven- 
tional treatment groups (Table 7). When paired echocardio- 
graphic variables at the in-hospital and the 6 month exami- 
nation were compared in these patients, no significant 
difference was found in either the streptokinase group or the 
control group for end-diastolic or end-systolic volume or 
ejection fraction (Fig. 5). Only regional wall motion index 
decreased slightly in streptokinase-treated patients (p = 0.08). 
The differences in ventricular volumes and regional wall 
motion detected at the curly examination persisted at follolzj- 
up (Fig. 6); the end-systolic volume was again strongly 
related to the extent of asynergy for both groups of patients 
(r = 0.63 and r = 0.66 respectively, p < 0.001 for both) (Fig. 
4B): for large and similar extents of regional dysfunction, 
volume was slightly smaller in the streptokinase than in the 
control group (p = 0.06). 
Discussion 
Streptokinase versus conventionally treated groups. The 
two-dimensional echocardiographic project of the GISSI 
trial suggests that left ventricular modeling and function are 
improved in patients with myocardial infarction treated with 
intravenous streptokinase compared with those assigned to 
Table 4. Echocardiographic Data by Previous Infarction in 330 Patients* 
NO 
SK C p Value SK 
YES 
C p Value 
No. of patients 
EDV (ml) 
ESV (ml) 
EF (%) 
RWMi 
(no. of segments) 
139 I41 22 28 
115.6 lr 48.7 130.0 2 53.9 0.019 143.2 + 50.6 156.4 ? 72.0 0.468 
62.9 i- 35.2 70.9 ? 40.4 0.079 80.4 + 41.0 94.4 -’ 64.1 0.37: 
46.9 i- 14.3 46.6 ? 14.6 0.886 45.1 i- 13.3 42.5 -’ 16.5 0.547 
2.1 ? I.8 2.7 ? 2.0 0.007 3.3 i 1.6 2.9 + I.6 0.432 
*Previous infarction was doubtful in I of 331 patients. Abbreviations as in Table 2. 
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Table 5. Echocardiographic Data by Site of Infarction in 331 Patients 
Anterior Other Site 
SK C p Value SK C p Value 
No. of patients 48 61 113 109 
EDV (ml) 124.3 ? 45.7 151.9 2 70.9 0.019 117.3 t 51.6 124.7 + 46.5 0.260 
ESV (ml) 13.7 + 39.8 91.4 2 57.3 0.069 61.6 + 34.6 65.7 f 34.7 0.410 
EF (%) 42.9 2 16.1 41.9 2 16.0 0.748 48.2 + 13.0 48.1 2 13.9 0.917 
RWMi 3.4 ” 1.9 3.8 2 1.9 0.227 1.8 ? 1.6 2.2 ? 1.7 0.095 
(no. of segments) 
Abbreviations as in Table 2. 
conventional treatment. Although no variation in ejection 
fraction was evident between the two groups, end-systolic 
volume was significantly smaller in streptokinase-treated 
patients. If one assumes that left ventricular systolic pres- 
sure was similar in the two groups, it seems reasonable to 
argue that the depression in left ventricular contractile state, 
secondary to myocardial infarction, was less pronounced in 
the treated than in the untreated patients (9). Finally, this 
difference in volume was not completely accounted for by 
the limiting effect exerted by streptokinase on the extent of 
the dysfunctioning area, and a concomitant restraining effect 
of the drug on the process of infarct expansion is postulated. 
Effect of streptokinase on left ventricular volume. Al- 
though most trials assessing the effects of thrombolytic 
agents on left ventricular function have focused on ejection 
fraction, the effects of thrombolysis on left ventricular 
volume after myocardial infarction have rarely been re- 
Table 6. Characteristics of 232 Patients With and 99 Patients 
Without Follow-up Echocardiogram 
Follow-up Yes 
No. of patients 232 
SK (%) 47.4 
Female (%) 13.8 
Age (yr) 57.3 + 11.5 
Time from the onset of 
symptoms (min) 231 + 152 
Previous infarct (%) 
No 84.5 
Yes 15.1 
Site of infarct (%) 
Anterior 29.3 
Inferior 34.5 
Lateral 2.2 
Multiple location 25.4 
ST depression 8.2 
Undefined 0.4 
EDV (ml) 119.2 5 49.6 
ESV (ml) 62.6 ” 35.3 
EF (%) 48.4 + 13.7 
RWMi (no. of 2.2 ” 1.8 
segments) 
Abbreviations as in Table 2. 
No 
99 
51.5 
12.1 
54.9 ” 15.1 
240 2 149 
84.9 
15.2 
41.4 
27.3 
7.1 
14.1 
10.1 
0.0 
145.1 ? 60.9 
88.2 + 49.6 
41.2 k 15.2 
3.2 ? 2.1 
p Value 
co.50 
co.70 
0.130 
0.631 
co.90 
10.01 
O.OOQl 
<0.0001 
<0.0001 
10.0001 
ported. Our data confirm that intravenous streptokinase 
limits the process of left ventricular dilation after myocardial 
infarction while reducing the extent of regional wall motion 
abnormalities (3,10-12). The strong relation between end- 
systolic volume and regional wall motion index, detected in 
both treatment groups in the early and the late study (Fig. 4), 
suggests that the primary beneficial effect of streptokinase 
would be in limiting infarct size and lessening subsequent 
deterioration in left ventricular function. However, for sim- 
ilar extent of regional dysfunction, end-systolic volume was 
smaller in patients assigned to thrombolytic treatment than 
in those assigned to standard care. Although of borderline 
significance, this finding suggests that thrombolysis should 
also prevent volume increase after myocardial infarction 
beyond its beneficial effects on infarct size, and it supports 
experimental and clinical data (13,14) suggesting that reper- 
fusion of the infarct-related artery should limit early infarct 
expansion, independently of myocardial salvage. It has been 
Table 7. Baseline Characteristics of 232 Patients With 
Follow-up Echocardiogram 
(n =“? IO) C (n = 122) 
Female (%) 18.2 9.8 
Age (yr) 
565 (%) 72.7 81.1 
>6S (%) 21.3 19.9 
Time from the onset of symptoms 
53 h (%) 49.0 56.6 
>3 to 6 h (%) 29.1 20.5 
>6 h (%;) 12.7 17.2 
Previous infarct (%) 
No 86.4 82.8 
Yes 13.6 16.4 
Doubtful 0.0 0.8 
Site of infarct (%) 
Anterior 24.5 33.6 
Inferior 32.7 36.1 
Lateral 3.6 0.8 
Multiple location 29.1 22.1 
ST depression 9.1 7.4 
Undefined 0.9 0.0 
Abbreviations as in Table 2. 
p Value 
co.25 
<o. 10 
<O.lO 
co.50 
<0.25 
JACC Vol. 14, No. 5 
November 1. 1989: 1149-58 
MARINO ET AL. 1155 
STREPTOKINASE AND VENTRICULAR FUNCTION 
reported (15), in fact, that the degree of infarct artery 
perfusion rather than infarct size is the most important 
predictor of changes in ventricular volume in the month after 
acute myocardial infarction. In a recent study, Jeremy et al. 
(15) showed that perfusion of the infarct-related artery 
during the healing phase of myocardial infarction may pre- 
vent continuing infarct expansion and subsequent left ven- 
tricular dilation. At each level of infarct size, patients in that 
study with an unperfused infarct-related artery showed a 
greater increase in volume than did patients with a perfused 
vessel. 
Although we are unable to submit angiographic data of 
patients enrolled in our echocardiographic project, it seems 
reasonable to argue that the number of reperfused infarct- 
related vessels should have been greater in the streptoki- 
nase- than in the conventionally treated group. This was the 
case for a cohort of 251 patients of the GISSI trial who 
underwent coronary angiography within 2 to 3 weeks after 
the acute episode (16): 67.7% of the patients who received 
thrombolytic treatment showed a patent infarct-related ves- 
sel, compared with 49.1% of those assigned to conventional 
treatment (p < 0.01). Similar results were also reported (17) 
for the Western Washington Intravenous Streptokinase Trial 
(17). 
One possible mechanism for this restraining effect of 
streptokinase on left ventricular volume increase after myo- 
cardial infarction. in excess of infarct size reduction, would 
be that reperfusion elicits edema of the heart and thus 
increases stiffness of the necrotic muscle, opposing infarct 
expansion (18). Alternatively, it could be hypothesized that 
reperfusion prevents expansion and dilation by preserving 
islands of epicardium (19). Because transmurality is an 
important determinant of infarct expansion, salvage of even 
a small rim of epicardial myocardium might be sufficient to 
prevent or lessen infarct expansion (20). 
Left ventricular volume and prognosis. If the functional 
status of the left ventricle has to be looked on as the major 
predictor of survival after myocardial infarction (21), then 
the observation of a less depressed contractile state in 
streptokinase-treated than in control patients may explain 
the significant reduction in mortality with thrombolytic treat- 
ment documented in the GISSI trial (1,2). The relation 
between functional status and survival, however, does not 
systematically fit the results of our stratification analysis. 
Although we anticipated that false negative results in some 
subgroups must be expected, the unpredictable absence of 
such a relation for some cohorts of patients is surprising. 
This is particularly the case when stratification according to 
“hours elapsed before randomization” is considered. 
Whereas there were significant differences in volumes and 
regional wall motion index between streptokinase-treated 
and control patients enrolled between 3 and 6 h from the 
onset of pain, and a clear (but nonsignificant) trend in this 
direction was also evident for patients enrolled after 6 h, the 
trend was much less clear for patients enrolled within 3 h of 
symptoms. The result is intriguing because, for this sub- 
group of patients, the reduction in in-hospital mortality after 
streptokinase is significantly less than that for patients 
treated conventionally in the GISSI trial (1,2) and in other 
large randomized trials (8,22) of a rapid high dose intrave- 
nous streptokinase regimen. 
One possible explanation is the marked beneficial effect 
exerted on mortality when the drug is infused early, thus 
skewing the surviving patient group, which would be com- 
posed of streptokinase-treated patients with a large infarct 
who would have died if not treated. This factor could 
minimize differences in left ventricular functional variables, 
assessed at the predischarge study, between streptokinase- 
treated and control patients randomized early. Alternatively, 
it is possible that the restraining effect of the drug on infarct 
expansion and volume increase becomes more evident with 
later infusion. Against this interpretation are the results on 
the effects of early treatment on left ventricular functional 
variables reported in other trials (22,23) in which patients 
treated by <3 h benefited more as assessed by ejection 
fraction determined angiographically. In both these studies, 
however, selection bias might have been introduced because 
patients were encouraged to undergo left heart catheteriza- 
tion at the discretion of their physician, thus likely excluding 
from the investigation “patients who were too well or too 
sick” (21). The noninvasive assessment of left ventricular 
function has certainly minimized this possibility, and this 
could explain the differences existing between these two 
trials and our study in the functional characteristics of 
patients treated early. 
Also, Mlhen patients were stratijied according to age, we 
found a slight discrepancy between myocardial function 
status and mortality data: in patients aged >65 years, in 
whom no significant reduction in mortality was observed in 
the GISSI trial (l), a striking reduction in ventricular vol- 
umes and regional wall motion index was evident after 
thrombolysis. This discrepancy is difficult to interpret, and 
might only reflect the limitations of subgroup analysis, as 
suggested by the results of the ISIS-2 trial (8). where benefit 
appeared to be independent of age. 
The strutijication according to site and histoy of previ- 
0~s infarction does not raise any conflict between left 
ventricular functional variables and mortality data, and it 
will not be discussed further. 
6 month follow-up. Patients lost to follow-up were char- 
acterized at predischarge examination by left ventricular 
functional variables significantly worse than those of pa- 
tients studied 6 months later (Table 6). The difference, which 
was due to a greater incidence of anterior myocardial infarc- 
tion in this subgroup (41.4% versus 29.3%), likely prevented 
the detection of the increase in ventricular volume between 
early and late examination (Fig. 5) that has been documented 
by others (15,24). Patients lost to follow-up, however, were 
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evenly distributed between the two groups and, therefore, 
their absence should have not constituted a bias in compar- 
ing streptokinase versus conventional therapy, although it 
could affect the longitudinal intragroup comparisons. 
The 6 month examination documented that the differ- 
ences in ventricular volumes and regional wall motion index 
detected on the predischarge study persisted at follow-up 
(Fig. 6). These findings, in agreement with those observed in 
relation to survival data (2), suggest that any study on the 
effects of thrombolysis on left ventricular function should 
probably focus on the hospital phase, because this is the 
Figure 6. Bar graph showing end-diastolic (EDV) and end-systolic 
volume (ESV), ejection fraction (EF) and regional wall motion index 
(RWMi) at the 6 month examination in patients who received 
streptokinase (SK) and in those assigned to conventional treatment 
(C). Again, ventricular volumes and regional wall motion index are 
significantly smaller in streptokinase-treated patients, although ejec- 
tion fraction does not differ between the two groups. 
f23SK tic 
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Figure 5. Paired comparisons of functional variables 
between predischarge and 6 month examination in pa- 
tients who received thrombolytic treatment (SK) and in 
those allocated to standard care (C). No significant 
difference is present, in either the streptokinase or the 
standard care group for volumes and ejection fraction 
between early and late study. Only regional wall motion 
index decreases slightly (p = 0.08) at 6 month control 
follow-up. 
period when the differences induced by the thrombolytic 
treatment usually arise. 
Limitations of the study. Several limitations must be 
pointed out. As an index of left ventricular function, end- 
systolic volume is afterload dependent (9). Therefore, the 
absence of data on peak systolic pressure at the time of 
two-dimensional echocardiography is a limiting factor in the 
study. In a recent trial (11) conducted by the Interuniversity 
Cardiology Institute in the Netherlands, however, left ven- 
tricular peak systolic pressure, assessed at predischarge 
angiography, was comparable between patients allocated to 
thrombolytic therapy and a control group (129 ? 2 versus 
127 ? 2 mm Hg). We think it is reasonable to assume that, in 
our study, a greater increase in left ventricular volume in 
patients assigned to conventional treatment compared with 
that in patients who received streptokinase does reflect a 
greater decrease in contractile state. 
To assess regional wall motion analysis, we used a 
semiquantitative method that relied on the number of aki- 
netic and dyskinetic segments in an 11 segment model; such 
a number, when used as a rough estimate of infarct size, 
overestimates its extent (25). However, it has been shown 
(26) that the circumferential extent of akinesia/dyskinesia 
and the circumferential extent of scar after myocardial 
infarction correlate closely. In this perspective, a graduated 
endocardial wall motion score index was purposely avoided, 
because experimental and clinical studies (25,26) have 
proved that absence rather than reduction of mechanical 
contraction is the most specific marker of infarcted myocar- 
dium. Furthermore, the heterogeneity of wall thickening and 
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endocardial excursion in the normal heart makes the defini- 
tion of hypokinesia and hyperkinesia difficult (27). 
This methodologic approach prevented us from the po- 
tential assessment of any difference in the extent of regional 
wall motion of remote myocardium of streptokinase-treated 
versus control patients, as recently suggested by the West- 
ern Washington Intravenous Streptokinase Trial (17). As in 
our study, differences in function in that study were most 
marked in patients with anterior infarction. A few studies 
(3,10,22) have documented an improvement also in patients 
with inferior infarction after thrombolysis; we cannot ex- 
clude that the single plane model used for volume and 
ejection fraction evaluation in our study might have under- 
estimated differences in inferior wall motion. 
Finally, some limitations stem from the design of the 
trial, which was a multicenter, unblinded study, with on site 
analysis of the echocardiographic data. It is reasonable to 
think that the analysis of the echocardiograms in a core 
laboratory would have improved the inter-laboratory repro- 
ducibility, minimizing the problems intrinsic to the echocar- 
diographic technique, particularly in the assessment of ven- 
tricular volumes. Furthermore, a central laboratory would 
have allowed more sophisticated analysis to be performed. 
like measurement of wall thickness and segment length 
between fixed landmarks to better address the problem of 
infarct expansion. This strategy, however, would have 
charged the core laboratory with an excessive burden and, in 
this light, the idea was considered unpractical at the time the 
echocardiographic project was conceived. 
Notwithstanding these /imitations, the “longitudinal” 
consistency of the quantitative and qualitative data (Fig. 5), 
together with their reasonable interlaboratory reproducibil- 
ity, seems to exclude the design of the trial to be the source 
of a major bias in the final results. 
Conclusion. The two-dimensional echocardiographic 
project of the GISSI trial supports the hypothesis that 
streptokinase therapy in patients with acute myocardial 
infarction lessens postinfarction left ventricular dilation, 
reducing the extent of regional wall motion abnormalities 
and, probably, avoiding infarct expansion. These beneficial 
effects on early ventricular modeling and function, which 
persist also in the chronic phase of the disease, may explain 
the striking reduction in mortality due to thrombolytic ther- 
apy in patients with acute myocardial infarction. 
Appendix 
Participating Centers in the Gruppo Italian0 per lo Studio della 
Streptochinasi nell’Infarto Miocardico Two-Dimensional Echocar- 
diographic Project are: 
Cattedra e Divisione Clinicizzata di Cardiologia4sp. “Borg0 
Trento”-Verona: G. Golia, M.A. Prioli, L. Scazzina. E. Moschini. 
R. Bonmassari. 
Servizio di Cardiologia-Ospedale Civile Belluno: G. Catania, G. 
Soravia. 
Divisione di Cardiologia-Presidio Ospedaliero di Caserta: B . 
Castellano, A. Di Fuccia. 
Presidio Ospedaliero di Castelfranco Veneto: F. Rigo, L. Celegon. 
I Divisione di Cardiologia-Ospedale “S. Martino”-Genova: R. 
Delfino, E. Oldoino, G. Secchi, P. Rossi. 
Istituto di Fisiopatologia Cardiorespiratoria-Osp. “S. Carlo Bor- 
romeo”-Milano: F. Casazza, D. Cirino, F. Regalia, A. Tavecchia. 
Divisione di Cardiologia4entro “De Gasperis”-Niguarda Mi- 
lane: A. Pezzano, M. Frigerio. 
Ospedale Civile di Modena: F. Melandri, G. Alfano, M.C. Tesor- 
ieri. P. Moracchini. 
Divisione di Cardiologia-Ente Ospedaliero di Monza: R. Schia- 
vina, F. Valagussa. 
Divisione di Cardiologia-Ospedale “G. Da Procida”-Salerno: 
C. Baldi, M. De Cristofaro, M. Petrone. 
Divisione di Cardiologia-Ospedale di Seriate: F. Colombo, G. 
Ferrario, V. Giudici, P. Giani. 
Cattedra Malattie Apparato Cardiovascolare-Osp. “Moli- 
nette”-Torino: D. Montemurro. 
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